ClinicalTrials.gg
RecruitingNCT06785597Updated Jan 21, 2025

EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms

An observational study in Mixed Neuroendocrine-Non Neuroendocrine Neoplasm and Neuroendocrine Neoplasm, sponsored by European Institute of Oncology. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-21.

Sponsored by European Institute of Oncology · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 68 studies in Neuroendocrine Tumors with a site in Italy — 20 open to participants now, 24 under way, 5 of them phase 3. Neuroendocrine Tumors · Italy.

Planned enrollment
11th of 18
130 · median 252
Started
2024
with 1 other
Observational
18 of 68
12 open now
Primary completion
2026-10
later than 11 of 23 live
Registered
65th of 68
by date
Lead sponsor
8 of 68
European Institute of Oncology

Among the 68 studies in Neuroendocrine Tumors with a site in Italy, this one is the 11th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2024, is one of 18 observational ones, reaches primary completion later than 11 of the 23 other live ones, and was the 65th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

20 of the 68 studies in Neuroendocrine Tumors with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Neuroendocrine Tumors with a site in Italy, or all of them as a file.
02

Study summary

For GEP mixed neuroendocrine (NE) non-neuroendocrine neoplasms (MiNENs) a key issue affecting prognosis is sometimes the difficulty in obtaining a timely diagnosis, as the NE component is often localized in deeper anatomical locations and/or becomes prevalent over time. The tissue material of biopsies may be not enough to define the NE component when this is particularly small and this could impact on therapeutic decision. Furthermore GEP NENs need to be characterized for potentially druggable biomarkers and liquid biopsy has clear advantage to the solid one to this aim. Here, we will exploit epigenetic differences characterizing NE tumors to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of NE derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.

Read the detailed description

GEP-NENs are a heterogeneous group of diseases that encompasses relatively indolent and more aggressive tumors, sometimes with mixed exocrine/endocrine components (MINENs). Due to persistent uncertainties in diagnosis and treatment, prognosis of the mixed and more aggressive forms remains poor. Non-invasive tests would enable timely identification and monitoring over time. A better understanding of their biology and of the phenotypic differentiation process may pave the way for novel therapies. Differentiation follows, and can be inferred from, changes in the epigenetic landscape that shape transcriptional programs. Among epigenetic markers, DNA methylation is particularly well suited for non-invasive detection as it can be measured in circulating tumor DNA (ctDNA). New technologies like Oxford Nanopore Technologies (ONT) enable simultaneous analysis of DNA sequence and methylation, as we recently showed by Magi et al Nat Comms Biol 2022. Previous studies identified distinct neuroendocrine epi-transcriptomic landscapes but were conducted on tumor specimens (Yachida et al Cancer Discov 2022), impeding the discrimination of signals specifically generated within neuroendocrine tumor cells from the noise due to surrounding nontumoral or exocrine tumoral cells. This is now potentially solved by methods allowing single-cell sequencing directly from frozen or paraffin-embedded patient samples.

The main expected outcome is the development of a novel liquid biopsy assay for the detection and monitoring of GEP-NENs and MiNENs. To this end, we will exploit the ability of Oxford Nanopore Technologies (ONT) sequencing to simultaneously yield sequencing and methylated DNA profiles. Importantly, assessment of cell of origin from ctDNA requires the comparison of methylation and fragmentomics signals with previously generated maps of reference cells and tissues (Katsman et al 2022 Genome Biology). For rare tumors like NENs, these maps are not available in the literature; the few studies that have characterized the epigenomic features of NENs are likely contaminated by the surrounding stroma, so epigenetic signals (including both DNA methylation and tumor-specific transcription factor binding sites, essential for fragmentomics) may be uninformative for detection in the blood.

03

Conditions studied

  • Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
  • Neuroendocrine Neoplasm

Browse trials for

Keywords

  • global molecular profiling
  • neuroendocrine phenotype
  • biomarker
  • epigenomic determinant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with GEP-NENs, aiming to collect adequate material and for a formal clinical to establish sensitivity and specificity of the assay in a clinically meaningful scenario.

Due to the relative rarity of the disease compared to non-NENs we will not enroll a consecutive population, but we will set up a case-control study:

  • Cases: patients with resectable, histologically confirmed NENs
  • Controls: patients with resectable, histologically confirmed non-neuroendocrine gastrointestinal tumors (including gastric, pancreatic, colorectal, small intestine).

Patients will be enrolled as cases or controls based on their pre-surgical diagnostic biopsy but will be definitively allocated in the case or control group based on their post-surgery full histological examination.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with confirmed diagnosis of NEC/MINEN amenable to surgery with radical intent
  • Patient with histologically confirmed diagnosis of NET amenable to surgery with radical intent
  • Patient with NET/NEC, amenable to or surgery, including palliative intent
  • Patient histologically confirmed non-NEN histotype:

    1. Colorectal carcinoma
    2. Small intestine carcinoma
    3. Gastric or oesophageal carcinoma
    4. Pancreatic ductal adenocarcinoma
    5. Metastasectomy from any non-NEN GI carcinoma

Exclusion criteria

Exclusion Criteria:

  • Grading G1 and G2 \<=10% Ki67
  • Presence of concomitant neoplasm (within 3 years)
  • Concomitant major haematological alteration
  • Concomitant major organ dysfunction (e.g. G3/4 liver or kidney failure)
  • Ongoing chemotherapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Neuroendocrine neoplasm case

    patient with histologically confirmed neuroendocrine neoplasm and onfirmed Mixed Neuroendocrine-non neuroendocrine neoplasm with each component \> 30%) and high-grade Neuroendocrine Carcinomas

  • Non-neuroendocrine neoplasm control

    patient with histologically confirmed non-neuroendocrine gastrointestinal tumors (including gastric, pancreatic, colorectal, small intestine).

06

What researchers measure

Primary outcomes

  1. Develop a circulating methDNA/fragmentomics diagnostic assay

    Epigenetic differences characterizing neuroendocrine tumors will be exploited to build a DNA methylation-based liquid biopsy assay able to detect circulating tumor DNA of neuroendocrine derivation, to enable the non-invasive diagnosis and monitoring of GEP-MiNENs.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • European Institute of Oncology
    Milan, 20141, Italy
    Recruiting
    • Nicola Fazio, MD,PhD · Contactdivisione.gastrointestinale@ieo.it · 0257489258
    • Nicola Fazio, MD,PhD · Contact
    • Francesca Spada, MD · Contact
    • Luca Mazzarella, MD · Contact
    • Lorenzo Gervaso, MD · Contact
    • Chiara Alessandra Cella, MD · Contact
    • Elenora Pisa, MD · Contact
    • Chiara Maria Grana, MD · Contact
    • Emilio Bertani, MD · Contact
    • Giuseppe Badalamenti, MD · Contact
    • Laura Algeri, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 54 observational studies under Neuroendocrine Tumors, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 239. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 21, 2025
StartActual
Oct 21, 2024
Primary completionEst.
Oct 21, 2026
CompletionEst.
Oct 21, 2026
Last update
Jan 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06785597
Collaborators
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Responsible party
Sponsor
First posted
Jan 21, 2025
Start date
Oct 21, 2024
Primary completion
Oct 21, 2026 (estimated)
Completion
Oct 21, 2026 (estimated)
Last update
Jan 21, 2025

Study contacts

Nicola Fazio, MD
Contact
divisione.gastrointestinale@ieo.it
0257489258
Francesca Spada, MD
Contact
divisione.gastrointestinale@ieo.it
0257489258
Nicola Fazio, MD
principal investigator · European Institute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion